I’ll start out this week with a clip from our live management briefing Skull Session with the CEO of BIOREM…covering Q4 2025 results, a record backlog, and the company’s view on the geopolitical environment, with the discussion reinforcing improving near-term visibility, supported by stronger order flow and backlog expansion.
I love that the CEO is incredibly transparent about how to think about the potential quarter-to-quarter lumpiness in the business, within a favorable long-term growth outlook. The stock is currently selling at a trailing P/E 12.6x.
The main development this week was the introduction of Cvd Equipment Corporation (NASDAQ:CVV) as a special situation, alongside the publication of our Reasons For Tracking note. CVV has long been a structurally challenged, loss-making business, but a recent asset sale (SDC unit) and data center narrative could have meaningfully reshaped the setup. With a stronger cash position and a debt-free real estate base that’s recorded on the balance sheet at well below market prices, we argued that the stock was trading comfortably below our book value calculation, even before assigning value to the operating business.